# Thymulin Clinical Dosing Guidelines

## Overview
Thymulin (also known as thymic factor or facteur thymique serique) is a nonapeptide hormone produced by thymic epithelial cells. It requires zinc for biological activity and plays a crucial role in T-cell differentiation, immune function enhancement, and anti-inflammatory responses.

## Clinical Research Summary
Based on clinical trials and research studies, thymulin has demonstrated efficacy in:
- Immune system modulation and enhancement
- Treatment of immunodeficiency disorders
- Anti-inflammatory and analgesic effects
- Cytokine storm mitigation (COVID-19 studies)
- Age-related immune decline reversal
- Autoimmune condition management

## Standard Concentrations

### Reconstitution Options
- **Option 1**: 0.15 mg/ml (dilute 1.5 mg in 10 ml bacteriostatic water)
- **Option 2**: 0.1 mg/ml (dilute 1 mg in 10 ml bacteriostatic water)
- **Option 3**: 0.05 mg/ml (dilute 1 mg in 20 ml bacteriostatic water)

### Storage
- **Lyophilized**: Store at -4°F, stable for 24+ months
- **Reconstituted**: Store at 39°F, use within 28 days
- **Zinc Requirement**: Ensure zinc availability for biological activity

## Clinical Dosing Protocols

### Subcutaneous Administration (Primary Route)

#### Standard Immune Support Protocol:
- **Concentration**: 0.1 mg/ml
- **Dose**: 0.015 mg per injection (15 mcg/220 lbs)
- **Volume**: 0.15 ml
- **Frequency**: Daily for acute conditions, 3x weekly for maintenance
- **Duration**: 4-12 weeks depending on indication

#### Anti-Inflammatory Protocol:
- **Concentration**: 0.15 mg/ml
- **Dose**: 0.001-0.025 mg per injection (1-25 mcg)
- **Volume**: 0.007-0.17 ml
- **Frequency**: Daily during inflammatory episodes
- **Duration**: 7-21 days for acute inflammation

#### Aging/Immunosenescence Protocol:
- **Concentration**: 0.1 mg/ml
- **Dose**: 0.01-0.02 mg per injection
- **Volume**: 0.1-0.2 ml
- **Frequency**: 3 times weekly
- **Duration**: 12-24 weeks with monitoring

### Intravenous Administration (Clinical Setting Only)

#### Severe Immunodeficiency:
- **Concentration**: 0.05 mg/ml
- **Dose**: 0.005-0.015 mg per injection
- **Volume**: 0.1-0.3 ml
- **Frequency**: Daily to every other day
- **Administration**: Slow IV push over 2-3 minutes

## Dose Calculations by Body Weight

### Standard Dosing (0.068 mcg/lb)
| Body Weight | Dose (mg) | Volume (0.1 mg/ml) | Volume (0.15 mg/ml) |
|-------------|-----------|-------------------|-------------------|
| 110 lbs | 0.0075 mg | 0.075 ml | 0.05 ml |
| 132 lbs | 0.009 mg | 0.09 ml | 0.06 ml |
| 154 lbs | 0.0105 mg | 0.105 ml | 0.07 ml |
| 176 lbs | 0.012 mg | 0.12 ml | 0.08 ml |
| 198 lbs | 0.0135 mg | 0.135 ml | 0.09 ml |
| 220 lbs | 0.015 mg | 0.15 ml | 0.10 ml |

### High-Dose Protocol (0.136 mcg/lb - Acute Conditions)
| Body Weight | Dose (mg) | Volume (0.1 mg/ml) | Volume (0.15 mg/ml) |
|-------------|-----------|-------------------|-------------------|
| 110 lbs | 0.015 mg | 0.15 ml | 0.10 ml |
| 154 lbs | 0.021 mg | 0.21 ml | 0.14 ml |
| 198 lbs | 0.027 mg | 0.27 ml | 0.18 ml |
| 220 lbs | 0.030 mg | 0.30 ml | 0.20 ml |

### Low-Dose Maintenance (0.034 mcg/lb)
| Body Weight | Dose (mg) | Volume (0.05 mg/ml) | Volume (0.1 mg/ml) |
|-------------|-----------|-------------------|-------------------|
| 110 lbs | 0.0037 mg | 0.074 ml | 0.037 ml |
| 154 lbs | 0.0052 mg | 0.105 ml | 0.052 ml |
| 198 lbs | 0.0067 mg | 0.135 ml | 0.067 ml |
| 220 lbs | 0.0075 mg | 0.15 ml | 0.075 ml |

## Clinical Applications

### Immunodeficiency Disorders:
- **Concentration**: 0.1 mg/ml
- **Dose**: 0.01-0.02 mg daily
- **Duration**: 8-16 weeks
- **Monitoring**: CD4+ T-cell counts, immune function markers

### COVID-19/Cytokine Storm:
- **Concentration**: 0.15 mg/ml
- **Dose**: 0.015-0.025 mg daily
- **Duration**: 7-14 days
- **Combination**: Often with standard care protocols

### Autoimmune Conditions:
- **Concentration**: 0.1 mg/ml
- **Dose**: 0.005-0.015 mg every other day
- **Duration**: 12-24 weeks
- **Monitoring**: Inflammatory markers, symptom scores

### Cancer Adjuvant Therapy:
- **Concentration**: 0.1 mg/ml
- **Dose**: 0.01-0.02 mg 3x weekly
- **Duration**: Throughout treatment period
- **Goal**: Immune system support during chemotherapy

## Administration Guidelines

### Injection Technique:
1. Use 27-30 gauge, 0.5 inch needle for subcutaneous
2. Clean injection site with alcohol
3. Inject into fatty tissue of abdomen, thigh, or upper arm
4. Rotate injection sites to prevent lipodystrophy
5. Inject slowly and steadily

### Timing Considerations:
- **Optimal**: Morning administration for circadian alignment
- **Consistency**: Same time daily when possible
- **Food**: Can be taken with or without food
- **Zinc**: Ensure adequate zinc levels for activity

## Safety Parameters

### Baseline Testing:
- Complete blood count (CBC)
- Comprehensive metabolic panel
- Immune function markers (CD4+, CD8+ T-cells)
- Zinc levels
- Inflammatory markers (CRP, ESR)

### Monitoring During Treatment:
- Weekly CBC for first month
- Monthly immune function assessment
- Inflammatory marker trends
- Clinical symptom improvement
- Adverse event monitoring

### Contraindications:
- Known hypersensitivity to thymulin
- Active malignancy (relative contraindication)
- Severe zinc deficiency (correct first)
- Pregnancy/lactation (insufficient data)

### Adverse Effects:
- Generally well-tolerated
- Injection site reactions (mild)
- Rare: transient fatigue or headache
- No serious adverse events in clinical trials
- Potential hypoglycemia at very high doses

## Special Considerations

### Zinc Dependency:
- Thymulin requires zinc for biological activity
- Check and correct zinc deficiency before treatment
- Consider zinc supplementation during therapy
- Monitor zinc levels periodically

### Age-Related Dosing:
- **Elderly**: May require higher doses due to immunosenescence
- **Children**: Limited data, use with caution
- **Adults**: Standard dosing generally appropriate

### Drug Interactions:
- Minimal known interactions
- Monitor when used with immunosuppressants
- May enhance vaccine responses
- Consider timing with other immune modulators

## Clinical Endpoints

### Treatment Success Indicators:
- Improved T-cell counts and function
- Reduced inflammatory markers
- Enhanced immune response to pathogens
- Decreased infection frequency/severity
- Improved quality of life scores

### Duration Guidelines:
- **Acute Conditions**: 1-4 weeks
- **Chronic Immune Dysfunction**: 12-24 weeks
- **Maintenance Therapy**: Ongoing with periodic assessment
- **Preventive Use**: Seasonal or episodic dosing

### Combination Therapy:
- Often combined with zinc supplementation
- May be used with other immune modulators
- Consider with probiotic support
- Nutritional optimization recommended